A prostate-specific antigen doubling time of <6 months is prognostic for metastasis and prostate cancer-specific death for patients receiving salvage radiation therapy post radical prostatectomy
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1748-717X
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
A prostate-specific antigen doubling time of <6 months is prognostic for metastasis and prostate cancer-specific death for patients receiving salvage radiation therapy post radical prostatectomy ; volume:8 ; number:1 ; day:8 ; month:7 ; year:2013 ; pages:1-8 ; date:12.2013
Radiation oncology ; 8, Heft 1 (8.7.2013), 1-8, 12.2013
- Creator
-
Jackson, William C.
- Contributor
-
Johnson, Skyler B.
Li, Darren
Foster, Corey
Foster, Benjamin
Song, Yeohan
Schipper, Matthew
Shilkrut, Mark
Sandler, Howard M.
Morgan, Todd M.
Palapattu, Ganesh S.
Hamstra, Daniel A.
Feng, Felix Y.
SpringerLink (Online service)
- DOI
-
10.1186/1748-717X-8-170
- URN
-
urn:nbn:de:1111-201604097216
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:54 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Jackson, William C.
- Johnson, Skyler B.
- Li, Darren
- Foster, Corey
- Foster, Benjamin
- Song, Yeohan
- Schipper, Matthew
- Shilkrut, Mark
- Sandler, Howard M.
- Morgan, Todd M.
- Palapattu, Ganesh S.
- Hamstra, Daniel A.
- Feng, Felix Y.
- SpringerLink (Online service)
Other Objects (12)
Biomarkers for prostate cancer: prostate-specific antigen and beyond
The Additional Value of Free Prostate Specific Antigen to the Battery of Age-Dependent Prostate-Specific Antigen, Prostate-Specific Antigen Density and Velocity
Developing new age-specific prostate-specific antigen thresholds for testing for prostate cancer
Any decline in prostate-specific antigen levels identifies survivors scheduled for prostate-specific membrane antigen-directed radioligand therapy
Any decline in prostate‐specific antigen levels identifies survivors scheduled for prostate‐specific membrane antigen‐directed radioligand therapy
Prostate-specific antigen-based screening: controversy and guidelines
Prostate-specific antigen testing accuracy in community practice
Prostate cancer risk prediction based on clinical factors and prostate-specific antigen
Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen
A phase II trial of personalized peptide vaccination in castration-resistant prostate cancer patients: prolongation of prostate-specific antigen doubling time
Prostate-Specific Antigen Density: A Measurement to Differentiate Benign Hypertrophy of Prostate from Prostate Carcinoma
Prostate-specific antigen nadir within 1 year of radiotherapy combined with hormone therapy predicts cancer-specific mortality and biochemical recurrence-free survival in prostate cancer patients
Biomarkers for prostate cancer: prostate-specific antigen and beyond
The Additional Value of Free Prostate Specific Antigen to the Battery of Age-Dependent Prostate-Specific Antigen, Prostate-Specific Antigen Density and Velocity
Developing new age-specific prostate-specific antigen thresholds for testing for prostate cancer
Any decline in prostate-specific antigen levels identifies survivors scheduled for prostate-specific membrane antigen-directed radioligand therapy
Any decline in prostate‐specific antigen levels identifies survivors scheduled for prostate‐specific membrane antigen‐directed radioligand therapy
Prostate-specific antigen-based screening: controversy and guidelines
Prostate-specific antigen testing accuracy in community practice
Prostate cancer risk prediction based on clinical factors and prostate-specific antigen
Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen
A phase II trial of personalized peptide vaccination in castration-resistant prostate cancer patients: prolongation of prostate-specific antigen doubling time
Prostate-Specific Antigen Density: A Measurement to Differentiate Benign Hypertrophy of Prostate from Prostate Carcinoma
Prostate-specific antigen nadir within 1 year of radiotherapy combined with hormone therapy predicts cancer-specific mortality and biochemical recurrence-free survival in prostate cancer patients
Biomarkers for prostate cancer: prostate-specific antigen and beyond
The Additional Value of Free Prostate Specific Antigen to the Battery of Age-Dependent Prostate-Specific Antigen, Prostate-Specific Antigen Density and Velocity
Developing new age-specific prostate-specific antigen thresholds for testing for prostate cancer
Any decline in prostate-specific antigen levels identifies survivors scheduled for prostate-specific membrane antigen-directed radioligand therapy
Any decline in prostate‐specific antigen levels identifies survivors scheduled for prostate‐specific membrane antigen‐directed radioligand therapy
Prostate-specific antigen-based screening: controversy and guidelines
Prostate-specific antigen testing accuracy in community practice
Prostate cancer risk prediction based on clinical factors and prostate-specific antigen
Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen
A phase II trial of personalized peptide vaccination in castration-resistant prostate cancer patients: prolongation of prostate-specific antigen doubling time
Prostate-Specific Antigen Density: A Measurement to Differentiate Benign Hypertrophy of Prostate from Prostate Carcinoma